-
Therapeutic Category
- BETA-LACTAM ANTIBIOTICS
- ANTI-INFECTIVE DRUGS
- Pharmaceutical Form : Dry Powder for oral suspension
- Composition : Cefprozil anhydrous 250 mg/ 5 ml Susp
- Active Substance : Cefprozil anhydrous
INDICATIONS AND USAGE :
CEFEPROL (cefprozil) is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:
UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes .
Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including (beta)-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including (beta)-lactamase-producing strains). Acute Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including (beta)-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including (beta)-lactamase-producing strains).
LOWER RESPIRATORY TRACT Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including (beta)-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including (beta)-lactamase-producing strains).
SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes. Abscesses usually require surgical drainage.
OVERDOSAGE
Cefprozil is eliminated primarily by the kidneys. In case of severe overdosage, especially in patients with compromised renal function, hemodialysis will aid in the removal of cefprozil from the body.
DOSAGE AND ADMINISTRATION
CEFEPROL (cefprozil) is administered orally.
Renal Impairment
Cefprozil may be administered to patients with impaired renal function.
The following dosage schedulshould be used.
*Cefprozil is in part removed by hemodialysis; therefore, cefprozil should be administered after the completion of hemodialysis.
Hepatic Impairment No dosage adjustment is necessary for patients with hepatic impairment .